rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2024-529-534rsp-3639Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL RESEARCHСостояние аппендикулярной мышечной массы у женщин с ревматоидным артритом: фокус на иммунологические маркерыAppendicular lean mass in women with rheumatoid arthritis: Focus on immunological markershttps://orcid.org/0000-0002-2809-0197ДобровольскаяО. В.DobrovolskayaO. V.

Ольга Добровольская

115522, Москва, Каширское шоссе, 34а

Olga Dobrovolskaya

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A

olgavdobr@mail.ruhttps://orcid.org/0000-0003-0961-9785ДеминН. В.DeminN. V.

115522, Москва, Каширское шоссе, 34а

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-7661-3124ФеклистовА. Ю.FeklistovA. Yu.

115522, Москва, Каширское шоссе, 34а

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0001-6404-0042ДиатроптовМ. Е.DiatroptovM. E.

115522, Москва, Каширское шоссе, 34а

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0001-7501-9185СамаркинаЕ. Ю.SamarkinaE. Yu.

115522, Москва, Каширское шоссе, 34а

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0003-4739-4302ТоропцоваН. В.ToroptsovaN. V.

115522, Москва, Каширское шоссе, 34а

115522, Russian Federation, Moscow, Kashirskoye Highway, 34A

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202401112024625529534Copyright © Добровольская О.В., Демин Н.В., Феклистов А.Ю., Диатроптов М.Е., Самаркина Е.Ю., Торопцова Н.В., 20242024Добровольская О.В., Демин Н.В., Феклистов А.Ю., Диатроптов М.Е., Самаркина Е.Ю., Торопцова Н.В.Dobrovolskaya O.V., Demin N.V., Feklistov A.Y., Diatroptov M.E., Samarkina E.Y., Toroptsova N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3639

Цель исследования – определить связь между аппендикулярной мышечной массой (АММ) и иммунологическими маркерами сыворотки крови у женщин с ревматоидным артритом (РА).Материал и методы. У 200 женщин с РА (медиана возраста – 60,0 [52,5; 65,5] лет) проводилось определение АММ с помощью двухэнергетической рентгеновской абсорбциометрии для выявления наличия саркопенического фенотипа (СПФ); также выполнено определение уровня С-реактивного белка (СРБ), ревматоидного фактора, антител к циклическому цитруллинированному пептиду. У 87 пациенток исследовали уровни сывороточного миостатина, фоллистатина, интерлейкина 6 (ИЛ-6), рецепторов к ИЛ-6, инсулиноподобного фактора роста 1 (ИФР-1), адипонектина, лептина, фактора роста фибробластов 23 (ФРФ23), фактора некроза опухоли SF12 (superfamily member 12).Результаты. Пациентки, имевшие и не имевшие СПФ, различались по уровню СРБ (медиана – 8,6 [1,3; 22,2] и 5,6 [1,2; 17,4] мг/л соответственно; р=0,041) и лептина (медиана – 3,8 [2,4; 5,7] и 5,4 [3,8; 6,9] нг/мл соответственно; р=0,030). АММ коррелировала с уровнем СРБ, фоллистатина и лептина. В линейном многофакторном регрессионном анализе выявлена взаимосвязь между мышечной массой и фоллистатином (β=–0,35; р=0,007), ИФР-1 (β=–0,38; р=0,002), лептином (β=0,36; р=0,004) и ФРФ23 (β=0,33; р=0,008).Заключение. Проведенное исследование показало, что у больных РА состояние мышечной массы связано с уровнем фоллистатина, ИФР-1, лептина и ФРФ23.

Aim – to evaluate the association among appendicular lean mass and immunological markers of blood serum in women with rheumatoid arthritis (RA).Material and methods. 200 women with RA (median age – 60.0 [52.5; 65.5] years) were enrolled in the study. Using dual-energy X-ray absorptiometry appendicular lean mass (ALM) was measured to determine the sarcopenic phenotype of body composition. The assessment of C-reactive protein (CRP), rheumatoid factor, and antibodies to cyclic citrullinated peptide was also performed. The levels of serum myostatin, follistatin, interleukin 6 (IL-6), IL-6 receptors, insulin-like growth factor 1 (IGF-1), adiponectin, leptin, fibroblast growth factor 23 (FGF23), tumor necrosis factor SF12 (superfamily member 12) were studied in 87 patients.Results. According to the presence of the sarcopenic phenotype the patients differed in the levels of CRP (8.6 [1.3; 22.2] and 5.6 [1.2; 17.4] mg/l, respectively; p=0.041) and leptin (3.8 [2.4; 5.7] and 5.4 [3.8; 6.9] ng/ml, respectively; p=0.030). ALM correlated with the levels of CRP, follistatin and leptin. Linear multivariate regression analysis revealed the association between ALM index and follistatin (β=–0.35; p=0.007), IGF1 (β=–0.38; p=0.002), leptin (β=0.36; p=0.004) and FGF23 (β=0.33; p=0.008).Conclusion. The study showed that there is an association between the lean mass and the level of follistatin, IGF-1, leptin and FGF23 in patients with RA.

ревматоидный артритсаркопенияцитокиныадипокинымиокиныфоллистатинлептинфактор роста фибробластов 23rheumatoid arthritissarcopeniacytokinesadipokinesmyokinesfollistatinleptinfibroblast growth factor 23Исследование выполнено в рамках фундаментальной научной темы «Разработка междисциплинарной персонализированной модели оказания помощи пациентам с аутовоспалительными дегенеративными заболеваниями (остеоартрит, остеопороз, саркопения, подагра, пирофосфатная артропатия) и мультиморбидностью (ожирение, сердечно-сосудистые заболевания)» , регистрационный номер 1021051403074-2.ReferencesRosenberg I. Summary comments. Am J Clin Nutr. 1989;50:1231-1233. doi: 10.1093/ajcn/50.5.1231Rosenberg I. Summary comments. Am J Clin Nutr. 1989;50:1231-1233. doi: 10.1093/ajcn/50.5.1231Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual frame-work. Clin Pharmacol Ther. 2001;69:89-95. doi: 10.1067/mcp.2001.113989Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual frame-work. Clin Pharmacol Ther. 2001;69:89-95. doi: 10.1067/mcp.2001.113989Ladang A, Beaudart C, Reginster JY, Al-Daghri N, Bruyère O, Burlet N, et al. Biochemical markers of musculoskeletal health and aging to be assessed in clinical trials of drugs aiming at the treatment of sarcopenia: Consensus paper from an Expert Group Meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the Centre Académique de Recherche et d’Expérimentation en Santé (CARES SPRL), under the Auspices of the World Health Organization Collaborating Center for the Epidemiology of Musculoskeletal Conditions and Aging. Calcif Tissue Int. 2023;112:197-217. doi: 10.1007/s00223-022-01054-zLadang A, Beaudart C, Reginster JY, Al-Daghri N, Bruyère O, Burlet N, et al. Biochemical markers of musculoskeletal health and aging to be assessed in clinical trials of drugs aiming at the treatment of sarcopenia: Consensus paper from an Expert Group Meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the Centre Académique de Recherche et d’Expérimentation en Santé (CARES SPRL), under the Auspices of the World Health Organization Collaborating Center for the Epidemiology of Musculoskeletal Conditions and Aging. Calcif Tissue Int. 2023;112:197-217. doi: 10.1007/s00223-022-01054-zKo DS, Kim YH, Goh TS, Lee JS. Altered physiology of mesenchymal stem cells in the pathogenesis of adolescent idiopathic scoliosis. World J Clin Cases. 2020;8(11):2102-2110. doi: 10.12998/wjcc.v8.i11.2102Ko DS, Kim YH, Goh TS, Lee JS. Altered physiology of mesenchymal stem cells in the pathogenesis of adolescent idiopathic scoliosis. World J Clin Cases. 2020;8(11):2102-2110. doi: 10.12998/wjcc.v8.i11.2102Baker JF, England BR, George MD, Wysham K, Johnson T, Kunkel G, et al. Elevations in adipocytokines and mortality in rheumatoid arthritis. Rheumatology (Oxford). 2022;61(12):4924-4934. doi: 10.1093/rheumatology/keac191Baker JF, England BR, George MD, Wysham K, Johnson T, Kunkel G, et al. Elevations in adipocytokines and mortality in rheumatoid arthritis. Rheumatology (Oxford). 2022;61(12):4924-4934. doi: 10.1093/rheumatology/keac191Ngeuleu A, Allali F, Medrare L, Madhi A, Rkain H, Hajjaj-Hassouni N. Sarcopenia in rheumatoid arthritis: Prevalence, influence of disease activity and associated factors. Rheumatol Int. 2017;37(6):1015-1020. doi: 10.1007/s00296-017-3665-xNgeuleu A, Allali F, Medrare L, Madhi A, Rkain H, Hajjaj-Hassouni N. Sarcopenia in rheumatoid arthritis: Prevalence, influence of disease activity and associated factors. Rheumatol Int. 2017;37(6):1015-1020. doi: 10.1007/s00296-017-3665-xMüller R, Kull M, Põlluste K, Valner A, Lember M, Kallikorm R. Factors associated with low lean mass in early rheumatoid arthritis: A cross-sectional study. Medicina (Kaunas). 2019;55(11):730. doi: 10.3390/medicina55110730Müller R, Kull M, Põlluste K, Valner A, Lember M, Kallikorm R. Factors associated with low lean mass in early rheumatoid arthritis: A cross-sectional study. Medicina (Kaunas). 2019;55(11):730. doi: 10.3390/medicina55110730Dietzel R, Wiegmann S, Borucki D, Detzer C, Zeiner KN, Schaumburg D, et al. Prevalence of sarcopenia in patients with rheumatoid arthritis using the revised EWGSOP2 and the FNIH definition. RMD Open. 2022;8(2):e002600. doi: 10.1136/rmdopen-2022-002600Dietzel R, Wiegmann S, Borucki D, Detzer C, Zeiner KN, Schaumburg D, et al. Prevalence of sarcopenia in patients with rheumatoid arthritis using the revised EWGSOP2 and the FNIH definition. RMD Open. 2022;8(2):e002600. doi: 10.1136/rmdopen-2022-002600Navarro-Ibarra MJ, Saucedo-Tamayo MDS, Alemán-Mateo H, Parra-Sánchez H, Othón-Ontiveros P, Hernández J, et al. Association between interleukin 6 and C-reactive protein serum levels and body composition compartments and components in breast cancer survivors. Biol Res Nurs. 2024;26(2):231-239. doi: 10.1177/10998004231207022Navarro-Ibarra MJ, Saucedo-Tamayo MDS, Alemán-Mateo H, Parra-Sánchez H, Othón-Ontiveros P, Hernández J, et al. Association between interleukin 6 and C-reactive protein serum levels and body composition compartments and components in breast cancer survivors. Biol Res Nurs. 2024;26(2):231-239. doi: 10.1177/10998004231207022Wu X, Li X, Xu M, Zhang Z, He L, Li Y. Sarcopenia prevalence and associated factors among older Chinese population: Findings from the China Health and Retirement Longitudinal Study. PLoS One. 2021;16(3):e0247617. doi: 10.1371/journal.pone.0247617Wu X, Li X, Xu M, Zhang Z, He L, Li Y. Sarcopenia prevalence and associated factors among older Chinese population: Findings from the China Health and Retirement Longitudinal Study. PLoS One. 2021;16(3):e0247617. doi: 10.1371/journal.pone.0247617Morawin B, Tylutka A, Bielewicz F, Zembron-Lacny A. Diagnostics of inflammaging in relation to sarcopenia. Front Public Health. 2023;11:1162385. doi: 10.3389/fpubh.2023.1162385Morawin B, Tylutka A, Bielewicz F, Zembron-Lacny A. Diagnostics of inflammaging in relation to sarcopenia. Front Public Health. 2023;11:1162385. doi: 10.3389/fpubh.2023.1162385Сафонова ЮА. Серологические маркеры саркопении у людей в возрасте 65 лет и старше. Клиницист. 2023;17(4): 19-26.Safonova YuA. Serological markers of sarcopenia in ages 65 and over. The Clinician. 2023;17(4):19-26 (In Russ.). doi: 10.17650/1818-8338-2023-17-4-K687Lee SJ, Lee YS, Zimmers TA, Soleimani A, Matzuk MM, Tsuchida K, et al. Regulation of muscle mass by follistatin and activins. Mol Endocrinol. 2010;24(10):1998-2008. doi: 10.1210/me.2010-0127Lee SJ, Lee YS, Zimmers TA, Soleimani A, Matzuk MM, Tsuchida K, et al. Regulation of muscle mass by follistatin and activins. Mol Endocrinol. 2010;24(10):1998-2008. doi: 10.1210/me.2010-0127Bergen HR 3rd, Farr JN, Vanderboom PM, Atkinson EJ, White TA, Singh RJ, et al. Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: Insights using a new mass spectrometry-based assay. Skelet Muscle. 2015;5:21. doi: 10.1186/s13395-015-0047-5Bergen HR 3rd, Farr JN, Vanderboom PM, Atkinson EJ, White TA, Singh RJ, et al. Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: Insights using a new mass spectrometry-based assay. Skelet Muscle. 2015;5:21. doi: 10.1186/s13395-015-0047-5Maïmoun L, Mura T, Attalin V, Dupuy AM, Cristol JP, Avignon A, et al. Modification of muscle-related hormones in women with obesity: Potential impact on bone metabolism. J Clin Med. 2020;9(4):1150. doi: 10.3390/jcm9041150Maïmoun L, Mura T, Attalin V, Dupuy AM, Cristol JP, Avignon A, et al. Modification of muscle-related hormones in women with obesity: Potential impact on bone metabolism. J Clin Med. 2020;9(4):1150. doi: 10.3390/jcm9041150White TA, LeBrasseur NK. Myostatin and sarcopenia: Opportunities and challenges – A mini-review. Gerontology. 2014;60(4):289-293. doi: 10.1159/000356740White TA, LeBrasseur NK. Myostatin and sarcopenia: Opportunities and challenges – A mini-review. Gerontology. 2014;60(4):289-293. doi: 10.1159/000356740Nakashima M, Toyono T, Akamine A, Joyner A. Expression of growth/differentiation factor 11, a new member of the BMP/TGFbeta superfamily during mouse embryogenesis. Mech Dev. 1999;80(2):185-189. doi: 10.1016/s0925-4773(98)00205-6Nakashima M, Toyono T, Akamine A, Joyner A. Expression of growth/differentiation factor 11, a new member of the BMP/TGFbeta superfamily during mouse embryogenesis. Mech Dev. 1999;80(2):185-189. doi: 10.1016/s0925-4773(98)00205-6Baker JF, Von Feldt JM, Mostoufi-Moab S, Kim W, Taratuta E, Leonard MB. Insulin-like growth factor 1 and adiponectin and associations with muscle deficits, disease characteristics, and treatments in rheumatoid arthritis. J Rheumatol. 2015;42(11):2038-2045. doi: 10.3899/jrheum.150280Baker JF, Von Feldt JM, Mostoufi-Moab S, Kim W, Taratuta E, Leonard MB. Insulin-like growth factor 1 and adiponectin and associations with muscle deficits, disease characteristics, and treatments in rheumatoid arthritis. J Rheumatol. 2015;42(11):2038-2045. doi: 10.3899/jrheum.150280Jiang JJ, Chen SM, Chen J, Wu L, Ye JT, Zhang Q. Serum IGF-1 levels are associated with sarcopenia in elderly men but not in elderly women. Aging Clin Exp Res. 2022;34(10):2465-2471. doi: 10.1007/s40520-022-02180-2Jiang JJ, Chen SM, Chen J, Wu L, Ye JT, Zhang Q. Serum IGF-1 levels are associated with sarcopenia in elderly men but not in elderly women. Aging Clin Exp Res. 2022;34(10):2465-2471. doi: 10.1007/s40520-022-02180-2Chen HT, Chung YC, Chen YJ, Ho SY, Wu HJ. Effects of different types of exercise on body composition, muscle strength, and IGF-1 in the elderly with sarcopenic obesity. J Am Geriatr Soc. 2017;65(4):827-832. doi: 10.1111/jgs.14722Chen HT, Chung YC, Chen YJ, Ho SY, Wu HJ. Effects of different types of exercise on body composition, muscle strength, and IGF-1 in the elderly with sarcopenic obesity. J Am Geriatr Soc. 2017;65(4):827-832. doi: 10.1111/jgs.14722Tabara Y, Okada Y, Ochi M, Ohyagi Y, Igase M. Associations between adiponectin and leptin levels and skeletal muscle mass and myosteatosis in older adults: The Shimanami Health Promoting Program Study. Geriatr Gerontol Int. 2023;(23):444-449. doi: 10.1111/ggi.14582Tabara Y, Okada Y, Ochi M, Ohyagi Y, Igase M. Associations between adiponectin and leptin levels and skeletal muscle mass and myosteatosis in older adults: The Shimanami Health Promoting Program Study. Geriatr Gerontol Int. 2023;(23):444-449. doi: 10.1111/ggi.14582Memelink RG, Njemini R, de Bos Kuil MJJ, Wopereis S, de Vogel-van den Bosch J, Schoufour JD, et al. The effect of a combined lifestyle intervention with and without protein drink on inflammation in older adults with obesity and type 2 diabetes. Exp Gerontol. 2024;(190):112410. doi: 10.1016/j.exger.2024.112410Memelink RG, Njemini R, de Bos Kuil MJJ, Wopereis S, de Vogel-van den Bosch J, Schoufour JD, et al. The effect of a combined lifestyle intervention with and without protein drink on inflammation in older adults with obesity and type 2 diabetes. Exp Gerontol. 2024;(190):112410. doi: 10.1016/j.exger.2024.112410Teixeira LAC, Dos Santos JM, Parentoni AN, Lima LP, Duarte TC, Brant FP, et al. Adiponectin is a contributing factor of low appendicular lean mass in older community-dwelling women: A cross-sectional study. J Clin Med. 2022;11(23):7175. doi: 10.3390/jcm11237175Teixeira LAC, Dos Santos JM, Parentoni AN, Lima LP, Duarte TC, Brant FP, et al. Adiponectin is a contributing factor of low appendicular lean mass in older community-dwelling women: A cross-sectional study. J Clin Med. 2022;11(23):7175. doi: 10.3390/jcm11237175Baker JF, Katz P, Weber DR, Gould P, George MD, Long J, et al. Adipocytokines and associations with abnormal body composition in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2023;75(3):616-624. doi: 10.1002/acr.24790Baker JF, Katz P, Weber DR, Gould P, George MD, Long J, et al. Adipocytokines and associations with abnormal body composition in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2023;75(3):616-624. doi: 10.1002/acr.24790Si Y, Kazamel M, Benatar M, Wuu J, Kwon Y, Kwan T, et al. FGF23, a novel muscle biomarker detected in the early stages of ALS. Sci Rep. 2021;11(1):12062. doi: 10.1038/s41598-021-91496-6Si Y, Kazamel M, Benatar M, Wuu J, Kwon Y, Kwan T, et al. FGF23, a novel muscle biomarker detected in the early stages of ALS. Sci Rep. 2021;11(1):12062. doi: 10.1038/s41598-021-91496-6Fukasawa H, Ishigaki S, Kinoshita-Katahashi N, Niwa H, Yasuda H, Kumagai H, et al. Plasma levels of fibroblast growth factor-23 are associated with muscle mass in haemodialysis patients. Nephrology (Carlton). 2014;19(12):784-790. doi: 10.1111/nep.12333Fukasawa H, Ishigaki S, Kinoshita-Katahashi N, Niwa H, Yasuda H, Kumagai H, et al. Plasma levels of fibroblast growth factor-23 are associated with muscle mass in haemodialysis patients. Nephrology (Carlton). 2014;19(12):784-790. doi: 10.1111/nep.12333Avin KG, Vallejo JA, Chen NX, Wang K, Touchberry CD, Brotto M, et al. Fibroblast growth factor 23 does not directly influence skeletal muscle cell proliferation and differentiation or ex vivo muscle contractility. Am J Physiol Endocrinol Metab. 2018;315(4): E594-E604. doi: 10.1152/ajpendo.00343.2017Avin KG, Vallejo JA, Chen NX, Wang K, Touchberry CD, Brotto M, et al. Fibroblast growth factor 23 does not directly influence skeletal muscle cell proliferation and differentiation or ex vivo muscle contractility. Am J Physiol Endocrinol Metab. 2018;315(4): E594-E604. doi: 10.1152/ajpendo.00343.2017

The authors declare that there are no conflicts of interest present.